Literature DB >> 3113470

Determination of cell-free interleukin 2 receptor level in the serum of normal animals and of animals bearing IL-2 receptor positive tumours with high or low metastatic capacity.

V Schirrmacher, O Josimovic-Alasevic, H Osawa, T Diamantstein.   

Abstract

Serum levels of cell-free interleukin-2 receptors were elevated above normal in mice bearing the IL-2R positive T-cell lymphoma Eb or its highly metastatic variant ESb. Although ESb cells expressed less IL-2R molecules than Eb cells on their cell surface, serum receptor levels were raised more quickly in ESb than in Eb tumour bearing animals. Elevated IL-2R serum levels were a sensitive tumour marker in animals bearing the aggressive variant ESb but not in animals bearing the low metastatic line Eb. Peritoneal ascites tumour-bearing animals had higher serum IL-2R levels than corresponding animals with subcutaneously growing tumours. Thus, serum IL-2R levels in tumour-bearing animals were dependent on the tumour line and influenced by the site and mode of tumour growth.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3113470      PMCID: PMC2002049          DOI: 10.1038/bjc.1987.119

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Enzyme-linked immunosorbent assay of mouse interleukin-2 receptors.

Authors:  H Osawa; O Josimovic-Alasevic; T Diamantstein
Journal:  J Immunol Methods       Date:  1986-08-21       Impact factor: 2.303

2.  Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo.

Authors:  V Schirrmacher; G Shantz; K Clauer; D Komitowski; H P Zimmermann; M L Lohmann-Matthes
Journal:  Int J Cancer       Date:  1979-02       Impact factor: 7.396

3.  T-cell growth factor receptor in adult T-cell leukemia.

Authors:  J Yodoi; T Uchiyama; M Maeda
Journal:  Blood       Date:  1983-08       Impact factor: 22.113

4.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

5.  Antigenic variation in cancer metastasis: immune escape versus immune control.

Authors:  V Schirrmacher; M Fogel; E Russmann; K Bosslet; P Altevogt; L Beck
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

6.  Different expression of Lyt differentiation antigens and cell surface glycoproteins by a murine T lymphoma line and its highly metastatic variant.

Authors:  P Altevogt; J T Kurnick; A K Kimura; K Bosslet; V Schirrmacher
Journal:  Eur J Immunol       Date:  1982-04       Impact factor: 5.532

7.  Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VIII. Expression and shedding of Fc gamma receptors on metastatic tumor cell variants.

Authors:  V Schirrmacher; W Jacobs
Journal:  J Supramol Struct       Date:  1979

8.  Suppression of T cell responses through competition for T cell growth factor (interleukin 2).

Authors:  J Günther; W Haas; H Von Boehmer
Journal:  Eur J Immunol       Date:  1982-03       Impact factor: 5.532

9.  Metastatic potential severely altered by changes in tumor cell adhesiveness and cell-surface sialylation.

Authors:  M Fogel; P Altevogt; V Schirrmacher
Journal:  J Exp Med       Date:  1983-01-01       Impact factor: 14.307

10.  T cell growth factor receptors. Quantitation, specificity, and biological relevance.

Authors:  R J Robb; A Munck; K A Smith
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

View more
  3 in total

1.  The therapeutic efficacy of an anti-IL-2 receptor monoclonal antibody correlates with an increase in serum soluble IL-2 receptor levels.

Authors:  H D Volk; O Josimovic-Alasevic; M Gross; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

2.  Soluble interleukin 2 receptor in atopic eczema.

Authors:  G B Colver; J A Symons; G W Duff
Journal:  BMJ       Date:  1989-05-27

3.  Interleukin 2 receptor in patients with localized and systemic parasitic diseases.

Authors:  O Josimovic-Alasevic; H Feldmeier; K Zwingenberger; G Harms; H Hahn; M Shrisuphanunt; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.